Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
Uchida J, Machida Y, et al.Journal of Nephrology, 24(4): 515-521, 2011.
Aims
To evaluate the influence of angiotensin II type 1 receptor blocker (ARB) in normotensive renal transplant recipients with low grade albuminuria.
Interventions
40-80 mg valsartan daily for 6 months versus no treatment with angiotensin II type 1 receptor blocker.
Participants
35 renal transplant recipients.
Outcomes
Serum creatinine, serum potassium, haematocrit, estimated glomerular filtration rate (eGFR), urinary albumin excretion. Other clinical parameters included age at transplantation, blood pressure, post-transplant duration, donor type and body mass index.
Follow-up
6 months
CET Conclusions
In this small trial with a 6 month observational period 35 patients were randomised to either receiving ARB (valsartan) or continuing current management. Only normotensive patients, with or without antihypertensive treatment, were entered into the study and most patients were several years after transplantation. In this study the authors report that ARB does reduce low grade albuminuria in normotensive renal transplant recipients but this is associated with a very modest increase in serum creatinine and decrease in eGFR. These findings require much larger studies for validation.
Data analysis
Per protocol analysis
Trial registration
Not reported